1320 related articles for article (PubMed ID: 19179815)
1. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
Holtorf K
Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
[TBL] [Abstract][Full Text] [Related]
2. Response to "The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?".
Miller H
Postgrad Med; 2009 Jul; 121(4):172. PubMed ID: 19641285
[No Abstract] [Full Text] [Related]
3. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks.
Moskowitz D
Altern Med Rev; 2006 Sep; 11(3):208-23. PubMed ID: 17217322
[TBL] [Abstract][Full Text] [Related]
4. Bioidentical hormone therapy: a panacea that lacks supportive evidence.
Boothby LA; Doering PL
Curr Opin Obstet Gynecol; 2008 Aug; 20(4):400-7. PubMed ID: 18660693
[TBL] [Abstract][Full Text] [Related]
5. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
L'hermite M; Simoncini T; Fuller S; Genazzani AR
Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy in menopausal women: Past problems and future possibilities.
Schmidt JW; Wollner D; Curcio J; Riedlinger J; Kim LS
Gynecol Endocrinol; 2006 Oct; 22(10):564-77. PubMed ID: 17135036
[TBL] [Abstract][Full Text] [Related]
7. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
8. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
[TBL] [Abstract][Full Text] [Related]
9. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
L'Hermite M
Climacteric; 2017 Aug; 20(4):331-338. PubMed ID: 28301216
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
11. Bioidentical hormones.
Well E
Adv Nurse Pract; 2009 Sep; 17(9):37-8, 40-1. PubMed ID: 20000171
[No Abstract] [Full Text] [Related]
12. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
Simoncini T; Genazzani AR
Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
[TBL] [Abstract][Full Text] [Related]
13. [Hormone replacement therapy and cancer of the breast. 1. Does replacement therapy increase the risk of cancer of the breast?].
Ayres de Campos D; Barros H; Martinez de Oliveira J
Acta Med Port; 1997 Oct; 10(10):697-703. PubMed ID: 9477595
[TBL] [Abstract][Full Text] [Related]
14. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
Johansen OE; Qvigstad E
Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
[TBL] [Abstract][Full Text] [Related]
15. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer risk in postmenopausal women using estrogen-only therapy.
Lyytinen H; Pukkala E; Ylikorkala O
Obstet Gynecol; 2006 Dec; 108(6):1354-60. PubMed ID: 17138766
[TBL] [Abstract][Full Text] [Related]
17. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
Seeger H; Wallwiener D; Mueck AO
Horm Metab Res; 2003 Feb; 35(2):76-80. PubMed ID: 12734785
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
Mueck AO; Seeger H; Wallwiener D
Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
[TBL] [Abstract][Full Text] [Related]
19. Hormone therapy and the cardiovascular system: the critical role of progestins.
Sitruk-Ware RL
Climacteric; 2003 Oct; 6 Suppl 3():21-8. PubMed ID: 15018245
[TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy and risk of breast cancer: the role of progestins.
Stahlberg C; Pedersen AT; Lynge E; Ottesen B
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
